PRIMARY STUDY

Phytocannabinoids—A Green Approach toward Non-Alcoholic Fatty Liver Disease Treatment

Key Findings:  This review covers the existing knowledge base on the endocannabinoid system (ECS) and CB1 and CB2 receptors and their involvement in the development and progression of non-alcoholic fatty-liver disorder (NAFLD). A better understanding of this interaction could lead to potential therapeutic uses for cannabinoids in the treatment of NAFLD.

Type of Study:  Meta-analysis

Study Result:  Positive

Research Location(s):  Poland

Year of Pub:  2021


Cannabinoids Studied:  Cannabidiol (CBD), Tetrahydrocannabinol (THC), Cannabidiolic Acid (CBD-a), Tetrahydrocannabinolic Acid (THC-a), Anandamide (AEA), 2-Arachidonoyl Glycerol (2-AG), Endocannabinoid (unspecified), Tetrahydrocannabivarin (THCV)

Phytocannabinoid Source:  Unspecified

Receptors Studied:  CB1, CB2, PPAR - Alpha, PPAR - Beta Delta, PPAR - Gamma, PPARs




Citation:  Berk K, et al. Phytocannabinoids-A Green Approach toward Non-Alcoholic Fatty Liver Disease Treatment. J Clin Med. 2021; 10:(unknown pages). doi: 10.3390/jcm10030393

Authors:  Berk K, Bzdega W, Konstantynowicz-Nowicka K, Charytoniuk T, Zywno H, Chabowski A